Literature DB >> 11751418

Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer.

P L Olive1, C Aquino-Parsons, S H MacPhail, S Y Liao, J A Raleigh, M I Lerman, E J Stanbridge.   

Abstract

The presence of radiation-resistant hypoxic cells in some solid tumors is known to predict for relapse after radiotherapy. Use of an endogenous marker of hypoxia would be a convenient alternative to current methods that measure tumor oxygenation, provided the marker could be shown to reliably identify viable, radiation-resistant, hypoxic cells. Carbonic anhydrase 9 (CA9) is a transmembrane protein overexpressed in a wide variety of tumor types and induced by hypoxia. Using a monoclonal antibody and cell sorting, CA9-positive cells in SiHa cervical carcinoma xenografts growing in immunodeficient mice were found to be clonogenic, resistant to killing by ionizing radiation, and preferentially able to bind the hypoxia marker pimonidazole. CA9 and pimonidazole immunostaining were compared in formalin-fixed sections from tumors of 18 patients undergoing treatment for cancer of the cervix. Excellent colocalization was observed, although the area of the tumor section that bound anti-CA9 antibodies represented double the number of cells that bound anti-pimonidazole antibodies. Occasional regions staining with pimonidazole but not CA9 could be indicative of transient changes in tumor perfusion. Results support the hypothesis that CA9 is a useful endogenous marker of tumor hypoxia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11751418

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

Review 1.  Physiological and pathological responses to hypoxia.

Authors:  Carine Michiels
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

2.  Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia.

Authors:  Narges K Tafreshi; Mark C Lloyd; Joshua B Proemsey; Marilyn M Bui; Jongphil Kim; Robert J Gillies; David L Morse
Journal:  Mol Imaging Biol       Date:  2016-04       Impact factor: 3.488

3.  Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.

Authors:  Harun M Said; Adrian Staab; Carsten Hagemann; Giles H Vince; Astrid Katzer; Michael Flentje; Dirk Vordermark
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

Review 4.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

5.  Tumor-associated carbonic anhydrases are linked to metastases in primary cervical cancer.

Authors:  Joo-Young Kim; Hye-Jin Shin; Tae-Hyun Kim; Kwan-Ho Cho; Kyung-Hwan Shin; Bu-Kyoung Kim; Ju-Won Roh; Sun Lee; Sang-Yoon Park; You-Jin Hwang; Inn-Oc Han
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-14       Impact factor: 4.553

Review 6.  Novel approaches in the therapy of metastatic renal cell carcinoma.

Authors:  John S Lam; John T Leppert; Arie S Belldegrun; Robert A Figlin
Journal:  World J Urol       Date:  2005-04-05       Impact factor: 4.226

Review 7.  Molecular imaging of tumor hypoxia with positron emission tomography.

Authors:  Olivia J Kelada; David J Carlson
Journal:  Radiat Res       Date:  2014-03-27       Impact factor: 2.841

Review 8.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 9.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

10.  Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.

Authors:  J K J Ahlskog; C Schliemann; J Mårlind; U Qureshi; A Ammar; R B Pedley; D Neri
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.